Found: 4
Select item for more details and to access through your institution.
Comparison of change in lipoprotein(a) mass and molar concentrations by alirocumab and risk of subsequent cardiovascular events in ODYSSEY OUTCOMES.
- Published in:
- European Journal of Preventive Cardiology, 2024, v. 31, n. 10, p. e75, doi. 10.1093/eurjpc/zwae110
- By:
- Publication type:
- Article
Alirocumab in Pediatric Patients With Heterozygous Familial Hypercholesterolemia: A Randomized Clinical Trial.
- Published in:
- JAMA Pediatrics, 2024, v. 178, n. 3, p. 283, doi. 10.1001/jamapediatrics.2023.6477
- By:
- Publication type:
- Article
Long-Term Efficacy, Safety, and Tolerability of Alirocumab in 8242 Patients Eligible for 3 to 5Years of Placebo-Controlled Observation in the ODYSSEY OUTCOMES Tria.
- Published in:
- Journal of the American Heart Association, 2023, v. 12, n. 18, p. 1, doi. 10.1161/JAHA.122.029216
- By:
- Publication type:
- Article
Efficacy and Safety of Single-Pill Combination of Rosuvastatin and Ezetimibe in Chinese Patients with Primary Hypercholesterolemia Inadequately Controlled by Statin Treatment (ROZEL): A Randomized, Double-Blind, Double Dummy, Active-Controlled Phase 3 Clinical Trial
- Published in:
- Advances in Therapy, 2023, v. 40, n. 12, p. 5285, doi. 10.1007/s12325-023-02666-z
- By:
- Publication type:
- Article